Stoke Therapeutics Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics or view top-rated stocks.

Wall Street analysts have given Stoke Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stoke Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Stoke Therapeutics.

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its quarterly earnings results on Monday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.02.
View Stoke Therapeutics' earnings history.

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STOK stock has increased by 92.4% and is now trading at $37.97.
View which stocks have been most impacted by COVID-19.

9 brokerages have issued 1-year price objectives for Stoke Therapeutics' shares. Their forecasts range from $35.00 to $76.00. On average, they anticipate Stoke Therapeutics' share price to reach $60.14 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price.
View analysts' price targets for Stoke Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Stoke Therapeutics include Ionis Pharmaceuticals (IONS), I-Mab (IMAB), TG Therapeutics (TGTX), Schrödinger (SDGR), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Galapagos (GLPG), Blueprint Medicines (BPMC), Hypera (HYPMY), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA) and Turning Point Therapeutics (TPTX).
View all of STOK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (9.93%), Redmile Group LLC (6.93%), Gilder Gagnon Howe & Co. LLC (3.45%), Federated Hermes Inc. (2.38%), Price T Rowe Associates Inc. MD (1.70%) and Goldman Sachs Group Inc. (1.52%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Robin A Walker, Rtw Investments, Lp and Stephen J Tulipano.
View institutional ownership trends for Stoke Therapeutics.

STOK stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Redmile Group LLC, Price T Rowe Associates Inc. MD, Federated Hermes Inc., Acuta Capital Partners LLC, Goldman Sachs Group Inc., Victory Capital Management Inc., and Northern Trust Corp. Company insiders that have sold Stoke Therapeutics company stock in the last year include Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Robin A Walker, and Stephen J Tulipano.
View insider buying and selling activity for Stoke Therapeutics or view top insider-selling stocks.

STOK stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Sphera Funds Management LTD., RTW Investments LP, Millennium Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Citigroup Inc., and Rafferty Asset Management LLC. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics or or view top insider-buying stocks.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STOK stock can currently be purchased for approximately $37.97.

Stoke Therapeutics has a market capitalization of $1.39 billion. The company earns $-52,240,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

Stoke Therapeutics employs 79 workers across the globe.

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

Stoke Therapeutics is headquartered at 45 WIGGINS AVENUE, BEDFORD MA, 01730.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]